Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

Launches are won in the plumbing, and this earnings season shows it

From Liquidia to Tonix to Autolus, the quarter's strongest numbers came from access, shipments and manufacturing execution, not from the label alone.

17 Nov 2026 · CompePharma editorial

The label gets you a launch. The plumbing gets you a business.

Read this batch of third-quarter results for what changed rather than what was approved, and a pattern emerges. The companies posting the most convincing numbers are the ones that have turned a product into a working operating system. That means access agreements, patient shipments and manufacturing throughput. CompePharma's view is that this is now the main differentiator among commercial-stage biopharma, and that too many leadership teams still treat it as the work that follows the science rather than part of it.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →
Opinion · CompePharma View

Gross margin is the number that turns a launch into a business

Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.

18 Nov 2026 · CompePharma editorial